Thera-SAbDab

FIGITUMUMAB

>   Structural Summary
TherapeuticFigitumumab
TargetIGF1R
Heavy ChainEVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS
Light ChainDIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-I
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedPfizer
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer, Colorectal cancer, Gastrointestinal cancer, Gynaecological cancer, Multiple myeloma, Non-small cell lung cancer, Prostate cancer, Rheumatoid arthritis, Sarcoma, Small cell lung cancer, Solid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]